MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


IP Group portfolio firm Microbiotica reports positive trial results

ALN

IP Group PLC on Wednesday said portfolio company Microbiotica Ltd has announced positive results from a phase 1b first-in-human trail of MB310 in ulcerative colitis patients.

The London-based investor in science and technology companies said Microbiotica is a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines.

IP Group has an undiluted beneficial holding of around 17% in Cambridge, England-based Microbiotica, valued at £13.9 million at the end of June.

Microbiotica noted that MB310 met its primary and secondary study objectives being safe and well tolerated, with successful engraftment of the MB310 bacteria.

It added that there were statistically significant improvements in efficacy parameters compared with placebo at the end of study assessments.

Clinical remission was achieved in 63% of MB310 treated patients compared to 30% in placebo treated patients.

Ulcerative colitis is an inflammatory bowel disease which affects over 1.4 million people globally.

‘We are very excited about these promising results. MB310 has the potential to be a new, differentiated treatment modality for patients with ulcerative colitis, offering the hope of long-lasting disease remission without side effects.,’ said Microbiotica Chief Executive Officer Tim Sharpington.

‘During 2026, we will explore partnering and financing options to determine the best route to fund our products through later studies and towards commercialisation.’

Shares in IP Group were down 1.5% at 58.30 pence on Wednesday afternoon in London.

Copyright 2026 Alliance News Ltd. All Rights Reserved.